Find participating medical centers and current study status in each of them

    Find participating medical centers

    A study to evaluate the safety and pharmacokinetics of the intravenous fixed-dose combination (IV FDC) of tiragolumab and atezolizumab in participants with locally advanced, recurrent or metastatic solid tumors

    A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors

    • Cancer
    • Solid Tumors
    • PD-L1-selected Solid Tumors

    For the latest version of this information please go to www.forpatients.roche.com